Tue, 16th Sep 2014 17:28
** Biotechnology company's shares up 3 pct at$13.94
** U.S. FDA approves oral therapy to treat opioid-inducedconstipation, co-developed with AstraZeneca Plc
** The drug will be sold under the trade name Movantik, andbe launched in the first half of 2015, the companies said
** Up to Monday's close, stock had gained about 19 pct thisyear
(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the Europ...
(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommend...
June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worse...
June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by abo...
(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:
Astrazeneca (AZN)